Cardiovascular death and non- fatal myocardial infarction in acute coronary syndrome patients receiv- ing coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119:237 42. 444. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopido- grel based on platelet function testing after percutaneous coronary inter- vention: the GRAVITAS randomized trial. JAMA. 2011;305:1097 105. 445. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust anti- platelet therapy for coronary stenting. N Engl J Med. 2012;367:2100 9. 446. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376:1312 9. 447. ShuldinerAR, O Connell JR, Bliden KP, et al.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849 57. Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e405 448. Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA boxed warning . Circulation. 2010;122:537 57. 449. Wenger NK, Froelicher ES, Smith LK, et al. Cardiac rehabilitation as secondary prevention. Agency for Health Care Policy and Research and National Heart, Lung, and Blood Institute. Clin Pract Guidel Quick Ref Guide Clin. 1995:1 23. 450. Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128:873 934. 451. Balady GJ, Williams MA, Ades PA, et al. 